# **JCI** insight

# FDXR variants cause adrenal insufficiency and atypical sexual development

Emanuele Pignatti, ..., Taosheng Huang, Christa E. Flück

JCI Insight. 2024. https://doi.org/10.1172/jci.insight.179071.

Research In-Press Preview Endocrinology Genetics

Genetic defects affecting steroid biosynthesis cause cortisol deficiency and differences of sex development; among them recessive mutations in the steroidogenic enzymes CYP11A1 and CYP11B, whose function is supported by reducing equivalents donated by ferredoxin reductase (*FDXR*) and ferredoxin. So far, mutations in the mitochondrial flavoprotein FDXR have been associated with a progressive neuropathic mitochondriopathy named FDXR-Related Mitochondriopathy (FRM), but cortisol insufficiency has not been documented. However, FRM patients often experience worsening or demise following stress associated with infections. We investigated two female FRM patients carrying the novel homozygous FDXR mutation p.G437R with ambiguous genitalia at birth and sudden death in the first year of life; they presented with cortisol deficiency and androgen excess compatible with 11-hydroxylase deficiency. In addition, steroidogenic *FDXR*-variant cell lines reprogrammed from three FRM patients' fibroblasts displayed deficient mineralocorticoid and glucocorticoid production. Finally, *Fdxr*-mutant mice allelic to the severe p.R386W human variant, showed reduced progesterone and corticosterone production. Therefore, our comprehensive studies show that human *FDXR* variants may cause compensated, but possibly life-threatening adrenocortical insufficiency in stress by affecting adrenal glucocorticoid and mineralocorticoid synthesis through direct enzyme inhibition, most likely in combination with disturbed mitochondrial redox balance.





https://jci.me/179071/pdf

1	FDXR variants cause adrenal insufficiency and atypical sexual development
2	Emanuele Pignatti <sup>1,2*</sup> , Jesse Slone <sup>3*</sup> , Maria Angeles Gomez-Cano <sup>4,5*</sup> , Teresa Margaret
3	Campbell <sup>3</sup> , Jimmy Vu <sup>3</sup> , Kay-Sara Sauter <sup>1,2</sup> , Amit V. Pandey <sup>1,2</sup> , Francisco Martínez-Azorín <sup>6,7</sup> ,
4	Marina Alonso-Riaño <sup>8</sup> , Derek E. Neilson <sup>9</sup> , Nicola Longo <sup>10</sup> , Therina du Toit <sup>1,2,11</sup> , Clarissa D.
5	Voegel <sup>2,11</sup> , Taosheng Huang <sup>3#</sup> , Christa E. Flück <sup>1,2#</sup>
6	* shared first/ # last authors for equal contribution
7	
8	<sup>1</sup> Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics,
9	Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
10	<sup>2</sup> Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland
11	<sup>3</sup> Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at
12	Buffalo, Buffalo, NY 14203, USA.
13	<sup>4</sup> Department of Pediatrics, Endocrinology Unit, 12 de Octubre University Hospital, Madrid,
14	Spain.
15	<sup>5</sup> UDISGEN (Unidad de Dismorfología y Genética), 12 de Octubre University Hospital, Madrid,
16	Spain.
17	<sup>6</sup> Grupo de Enfermedades Raras, Mitocondriales y Neuromusculares (ERMN). Instituto de
18	Investigación Hospital 12 de Octubre (imas12), E-28041 Madrid, Spain.
19	<sup>7</sup> Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), U723, E-
20	28041 Madrid, Spain.
21	<sup>8</sup> Pathology Department, 12 de Octubre University Hospital, Madrid, Spain.
22	<sup>9</sup> Division of Genetics and Metabolism, Department of Child Health, The University of Arizona
23	College of Medicine, Phoenix, AZ, USA.
24	<sup>10</sup> Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City,
25	Utah, USA.

- <sup>11</sup> Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University
- of Bern, 3010 Bern, Switzerland
- 28
- 29 <u>Corresponding authors:</u>
- 30 Christa E. Flück
- 31 University Children's Hospital Bern
- 32 Freiburgstrasse 65 / C845
- 33 3010 Bern
- 34 Switzerland
- 35 <u>christa.flueck@unibe.ch</u>
- 36
- 37 Taosheng Huang
- 38 Department of Pediatrics
- 39 Jacobs School of Medicine and Biomedical Sciences
- 40 University at Buffalo, Buffalo, NY 14203, USA.
- 41 taosheng.huang@gmail.com
- 42
- 43
- 44 **Conflict-of-interest statement:** The authors declare no conflict of interest.

45 **ABSTRACT** 

46 Genetic defects affecting steroid biosynthesis cause cortisol deficiency and differences of sex development; among them recessive mutations in the steroidogenic enzymes 47 CYP11A1 and CYP11B, whose function is supported by reducing equivalents donated by 48 49 ferredoxin reductase (FDXR) and ferredoxin. So far, mutations in the mitochondrial flavoprotein FDXR have been associated with a progressive neuropathic 50 51 mitochondriopathy named FDXR-Related Mitochondriopathy (FRM), but cortisol insufficiency has not been documented. However, FRM patients often experience 52 worsening or demise following stress associated with infections. We investigated two 53 female FRM patients carrying the novel homozygous FDXR mutation p.G437R with 54 ambiguous genitalia at birth and sudden death in the first year of life; they presented 55 with cortisol deficiency and androgen excess compatible with 11-hydroxylase deficiency. 56 57 In addition, steroidogenic FDXR-variant cell lines reprogrammed from three FRM patients' fibroblasts displayed deficient mineralocorticoid and glucocorticoid production. 58 59 Finally, *Fdxr*-mutant mice allelic to the severe p.R386W human variant, showed reduced 60 progesterone and corticosterone production. Therefore, our comprehensive studies 61 show that human FDXR variants may cause compensated, but possibly life-threatening adrenocortical insufficiency in stress by affecting adrenal glucocorticoid and 62 mineralocorticoid synthesis through direct enzyme inhibition, most likely in combination 63 with disturbed mitochondrial redox balance. 64

### 65 INTRODUCTION

66 Cortisol is the most important hormone for surviving acute stress related to severe life-67 threatening events such as infections. So far genetic variants have been described in humans for all enzymes involved in adrenal steroidogenesis leading to congenital adrenal hyperplasia 68 69 (CAH) defined by cortisol deficiency and lack or excess of androgen production depending on 70 the underlying specific defect and the chromosomal sex. Cortisol deficiency has also been 71 associated with variants in the genes for steroidogenic acute regulatory protein (STAR), which transports cholesterol into the mitochondria, and for the redox partner P450 oxidoreductase 72 73 (POR) (1, 2).

All cytochrome P450 steroid (CYP) enzymes involved in cortisol production depend on redox 74 75 partners for electron transfer (3). POR supports all type 2 microsomal CYP enzymes located in 76 the endoplasmic reticulum, including CYP17A1, CYP21A2, and CYP19A1 for steroid 77 biosynthesis. By contrast, type 1 CYP enzymes located in the mitochondria obtain reducing equivalents sequentially from the flavoprotein ferredoxin—NADP(+)-reductase and the 78 79 ferredoxins (FDXR/FDX) (Figure 1A). Among the mitochondrial type 1 enzymes, CYP11A1 and 80 CYP11B1 are essential for cortisol production, and CYP11B2 catalyzes aldosterone 81 biosynthesis. Although loss of activity of these enzymes leads to cortisol and/or aldosterone deficiency, variants in human FDXR or FDX have not been associated with adrenal disease so 82 83 far. However, inactivation of the related *Fdx1b* gene in zebrafish and the *dare* gene in Drosophila (an ortholog of human FDXR) results in defective steroid production, suggesting that 84 85 FDXR/FDX deficiency may lead to impaired steroidogenesis in humans (4-6). FDXR is normally not rate limiting for the activities of mitochondrial cytochrome P450 enzymes, but mutagenesis 86 of FDXR has been shown to affect the steroidogenic cytochrome P450 reactions (7), and also 87 88 showed higher Km and lower Vmax values for the reduction of FDX. 89 In 2017, autosomal recessive FDXR mutations were first reported in patients suffering from a

novel mitochondriopathy manifesting with optic atrophy and neuropathy (8, 9). As of June 2023,

91 77 patients have been described with numerous *FDXR* variants spread throughout the gene, 92 mostly missense mutations carried either in homozygosity or in compound heterozygosity 93 (Table S1) (8-18). The disease spectrum comprises visual and hearing defects and a broad 94 range of central and peripheral neuropathies. Affected individuals show variable degrees of 95 disease severity, with one group manifesting early in life and often worsening over time, 96 especially after intercurrent infections, and the other manifesting after the age of 2 years with 97 milder disease course (19).

We now describe two siblings with severe biallelic *FDXR* mutations manifesting at birth with optic atrophy, neuropathic hearing loss, global encephalopathy, and a 46,XX androgen excess leading to variation of sex development combined with adrenal insufficiency. We confirm pathogenicity of human *FDXR* mutations on steroidogenesis by functional studies performed in patient-derived reprogrammed adrenal cell lines and a mouse model of the disease. Thus, our work adds *FDXR* variants to the list of genes that may cause adrenal insufficiency and a novel form of syndromic 46,XX CAH featuring androgen excess.

105

#### 106 **RESULTS**

107 Disrupted adrenal steroidogenesis in index patients with autosomal recessive FDXR variation. 108 Two Equatoguinean siblings presented at birth with ambiguous genitalia and were found to have 109 a 46,XX androgen excess variation of sex development with normal uterus and ovaries. Soon after birth they were also diagnosed with a severe sensorial neuropathy compatible with an optic 110 111 atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome. Adrenal insufficiency was suspected in follow-up visits (Table 1 and Supplementary Information). Both 112 infants died in the first year of life due to infections and respiratory failure. Postmortem 113 114 examination of the adrenals of index patient 2 revealed slightly heavier adrenal glands with 115 minimal cytoplasmic vacuolization indicating lipid overload (Figure S3 and Supplementary Information). 116

117

118 WES analysis excluded variations in known CAH genes (such as HSD3B2, CYP21A2,

119 CYP11A1, CYP11B2, CYP11B1, and POR), but found a novel homozygous variant in the FDXR

120 gene: c.1309G>C (p.G437R) (Figure 1B and C). Both parents were healthy carriers.

121

122 Characteristics of reported patients with biallelic FDXR variants pointing at impaired
 123 steroidogenesis.

124 Review of the literature revealed 77 patients with 59 biallelic *FDXR* mutations (Figure 1D) presenting with visual and hearing defects and a broad range of central and peripheral 125 neuropathies (Supplementary Information) (10-18). Affected individuals show variable degrees 126 of disease severity, with one group manifesting early in life and often worsening with intercurrent 127 128 infections, and the other manifesting after the age of 2 years with milder disease course (19). 129 Many early-onset cases carried a specific variant (p.R386W) with high prevalence in the 130 Mexican population (19). Investigating for signs and symptoms of potential undiagnosed adrenal insufficiency (Table S1), we found a history of severe, often life-threatening events, or deadly 131 132 infections in 20 cases (26%). These events were mostly associated with a deterioration of preexisting signs of mitochondriopathy. Twelve patients died between 0.5-6 years, mostly 133 134 following an infection. Interestingly, we also found 2 patients with a genital phenotype. A boy was reported to have cryptorchidism and micropenis (16), while a girl was noted to have labial 135 136 fusion and clitoromegaly (13).

137

138 Reprogrammed patient-derived adrenal cell lines carrying FDXR variants show impaired
139 steroidogenesis.

To gain further insight into the effect of FDXR variants on steroidogenesis, we reprogrammed
three available dermal fibroblast lines originating from male patients into adrenal-like cell (iALC)
lines and assessed their steroid production along the three classical pathways of

143 mineralocorticoid, glucocorticoid, and androgen biosynthesis (Figure 2A). The patient with the 144 most severe disease phenotype (male patient II-2 in Peng et al. (9), diagnosed with delays in 145 motor development and poor visual tracking at 3 months of age and passed away at 17 months) 146 carried a homozygous mutation in the hotspot p.R386W. The other two patients, Case 2 in Peng 147 et al. (9), - p.F51L/p.G437S -, and Case 14 in Campbell et al. (19), - p.Q252\*, p.S132-E162del -, both males, had a later onset of neurological disease at age 2 and 4 years (Table S1). While 148 149 previous studies showed reduced FDXR expression in these patients' fibroblasts (9, 19), FDXR, 150 FDX1 and FDX2 RNA expression in the corresponding iALC was not significantly different compared to wild-type iALC (Figure S2). Steroid profiles of all three cell lines showed reduced 151 corticosterone, cortisone, and androgen production in comparison to a sex-matched control line 152 carrying a fully functional FDXR (Figure 2B and C). Cortisone was measured as a proxy for 153 154 cortisol, which was below the lowest accurate quantification threshold. Aldosterone was reduced 155 in two mutant lines, one corresponding to the most severe patient. Altogether, these data show that FDXR variants inhibit CYP11B2 and CYP11B1 enzymatic activities. In addition, the 156 suppression of the androgen pathway (Figure 2B) and the lower amounts of total steroid output 157 158 (Figure S1E) point at a lower conversion of cholesterol into pregnenolone precursor by 159 CYP11A1.

160

161 In silico analysis of FDXR variants

To understand how the variants in our index patients and in cells disrupt protein function, we performed computational modeling of the human FDXR structure (Figure 3A) and performed evolutionary analysis (Figure 3B), as well as interaction with FDX (Figure 3C) and structural flexibility studies (Figure 3D). All mutants studied in this report (in index patients and patientderived cell lines) were predicted to have negative impact either by increased rigidity that affects electron transfer within the FDXR from reduced nicotinamide adenine dinucleotide phosphate (NADPH) to flavin adenine dinucleotide (FAD), or via increased flexibility that affects the

interaction with FDX as well as the fine balance of intra-molecular movements that allow
electron transport from NADPH to FAD and binding and release of NADPH/NADP (Figure 3D,
Table S2, and Supplementary Information).

The presence of any of the described mutations in compound heterozygous form with other 172 173 structural mutants or mutations resulting in a truncated protein or non-sense mediated RNA decay are predicted to have severe disease-causing effects. We also built models of human 174 FDXR in complex with human FDX1 (Figure 3D) and found that none of the mutants described 175 in the current study were located at or near the FDXR-FDX interface. These studies are in 176 177 agreement with published crystal structures of the FDXR-FDX complex (20, 21) as well as a solution model based on paramagnetic NMR spectroscopy (7). Keizers et al (7) created mutants 178 of FDXR and found reduced affinity of FDX as well as lower activities of steroidogenic P450 179 180 CYP11A1. Crystal structure of the FDXR-FDX complexes as well as paramagnetic NMR model 181 of the complex agree with our docked structures which indicate a role of electrostatic interactions in the electron transfer between FDXR and FDX. A direct impact on any cytochrome 182 P450 could not be predicted due to indirect effect of FDXR interactions with the steroidogenic 183 cytochrome P450 activities. Nonetheless, due to predicted variable nature of protein-protein 184 185 interactions resulting from different conformational changes, a variable impact on the ability of FDX proteins to be reduced by mutant FDXR proteins is predicted. 186

187

A mouse model of the R386W hotspot mutation shows no alteration of adrenal development
 and zonal organization, but diminished corticosterone synthesis.

190 To assess whether FDXR variants in affected patients affect adrenocortical development,

191 zonation and steroidogenic function, we used a mouse model of the disease carrying the

192 p.R389W mutation (*Fdxr*<sup>R389W</sup>), allelic to the human p.R386W hotspot mutation characterized in

- 193 patients (Figure 4A). This mouse model has been generated in Jesse Slone's and Taosheng
- 194 Huang's lab at University of Buffalo, New York. Steroid profiling of mouse serum showed

decreased corticosterone levels, suggesting that FDXR supports CYP11B1 activity in mice too (Figures 4B and C). Histological analysis aided by zone-specific staining (Dab2 to identify the zona Glomerulosa (zG), and Akr1b7 to identify the zona Fasciculata (zF)) did not reveal any major defect of tissue organization or zonal arrangement (Figure 4D). Only the ratio between the areas occupied by the outer cortical zones (zG – producing aldosterone; and zF – producing corticosterone-) indicated an expansion of the zF at the expense of the zG (Figure 4E), which is compatible with chronically elevated ACTH due to primary adrenal insufficiency (22).

202

# 203 DISCUSSION

Here, we show that bi-allelic *FDXR* variants may cause potentially lethal adrenocortical

insufficiency and a 46,XX variation of sex development. This has not been recognized to date,

206 despite FDXR being an essential reducing partner to three steroid producing CYP enzymes

207 (CYP11A1, CYP11B1 and CYP11B2).

In the human adrenal cortex, cholesterol is converted to glucocorticoids and mineralocorticoids 208 209 through a series of enzymatic reactions (Figure 2A), whose disruption results in a range of 210 cortisol insufficiencies catalogued as congenital adrenal hyperplasia (CAH). Additionally, 211 precursor accumulation and diversion to the adrenal androgen pathway in 46,XX CAH may lead to androgen excess and consequent prenatal virilization of females with autosomal recessive 212 213 HSD3B2, CYP21A2, CYP11B1 and POR mutations. Typical of CYP11B1 deficiency is an increase in blood pressure with aging caused by the accumulation of precursors with 214 mineralocorticoid activity (23). The FDXR index patients reported here displayed both 215 216 ambiguous genitalia and elevated blood pressure, which recapitulates CAH due to deficiency of CYP11B1. Decreased glucocorticoids in the adrenal-like FDXR variant cell lines and the Fdxr 217 218 mouse were consistent with index patients' laboratory findings (Table 1), with reduced 219 mineralocorticoid production additionally evident in the in vitro models.

220 Cortisol deficiency with POR deficiency, the obligate redox partner of all type 2 endoplasmic 221 P450s enzymes (24), is only clinically relevant upon severe stress, while its impact on sex 222 steroids is often most prominent manifesting with a wide spectrum (25). Similarly, our index 223 patients with FDXR variants had adrenocortical insufficiency which might be subclinical and may 224 become life-threatening with infections triggering an adrenal crisis. However, whether the large 225 spectrum of stress responses in FDXR patients can be explained either by variant genotype or 226 other mechanisms such as cortisol deficiency needs to be established. It is important to note 227 that mitochondrial diseases are generally associated with increased susceptibility to infections, in some cases associated with reduced production and function of immune cells (26-28). 228 The steroid profile of our index 46,XX patients, which includes androgen excess, suggests that 229 CYP11A1 enzyme activity is less affected by FDXR insufficiency than CYP11B1. This might be 230 231 explained by the fact that the electron transport chain for CYP11A1 is relatively conservative, 232 losing only 15% of electrons, in contrast to a 40% loss associated with the CYP11B1 reaction, indicating that CYP11B1 may be more affected by an inefficient FDXR/FDX system (29). 233 234 Additionally, an analysis of CYP11/FDX complexes by surface plasmon resonance (SPR) 235 indicated that the association constant for the CYP11A1/FDX complex was higher compared to 236 the CYP11B1/FDX and CYP11B2/FDX complexes (30). This suggests a competition for available reduced FDXR between CYP11A1/FDX and CYP11B1/FDX complexes which favors 237 238 the CYP11A1-mediated reaction. Further, the SPR data indicated that the CYP11A1/FDX/FDXR complex is enthalpy-driven while CYP11B/FDX/FDXR complexes are entropy-driven, also 239 240 indicating that the intrinsic disorder in FDXR interactions may favor the CYP11A1 activity over CYP11B1. But additional studies using multiple combinations of WT and mutant FDXR proteins 241 with FDX and different steroidogenic cytochrome P450 proteins are needed to further 242 243 characterize the impact of mutations in FDXR on individual cytochrome P450 reactions and 244 overall steroidogenesis.

245 CAH can also be associated with mutations in the steroidogenic acute regulatory (STAR) 246 protein, responsible for importing cholesterol into mitochondria. Interestingly, STAR activity is 247 inversely regulated by changes of the mitochondrial redox homeostasis, which is strongly 248 affected in FRM patients (13), suggesting that STAR activity may also be compromised (14, 31). 249 STAR deficiency results in lipoid CAH, which presents as a two-hit model disease: first, 250 cholesterol transport into mitochondria is reduced; second, the progressive accumulation of 251 cholesterol depots results in cell death (32). We suspect that FDXR-associated adrenocortical 252 insufficiency could also be a progressive two-hit adrenal disorder, where the first genetic hit 253 causes reduced electron transfer to dependent steroidogenic enzymes, while the second hit consists of accumulation of reactive oxygen species and disruption of oxidative phosphorylation 254 associated with FDXR's role in Fe-S cluster assembly, inevitably causing cell death (9, 14). 255 256 Despite that, our Fdxr mouse model showed an almost normal cortex with only a slight 257 expansion of the zF at the expense of the zG. This discrepancy may be due to the young age at which the animal tissues were collected, which prevented us from exploring long-term 258 259 consequences of FDXR inactivation. 260 A recent systematic review concluded that adrenal insufficiency is seldom seen with 261 mitochondrial disorders although mitochondria play an important role for cortisol synthesis not only by harboring part of the steroid biosynthesis machinery, but also through ATP generation 262 and ROS detoxification (31, 33). Yet, subclinical cortisol deficiency was more often observed in 263 patients with mitochondrial diseases (e.g. Pearson Syndrome and Kearns-Sayre Syndrome) 264 265 when assessed by ACTH stimulation tests or with longitudinal evaluation (34). By contrast, primary adrenal insufficiency is a major phenotype of the peroxisomal disorder 266 adrenoleukodystrophy (ALD), in which very-long-chain fatty acids accumulate and lead to 267 268 cytotoxic destruction of the adrenal cortex, while a disturbed redox homeostasis is also involved 269 (35, 36). Like ALD, FDXR-related mitochondriopathy might affect steroidogenesis more often

and more severely than other mitochondrial disorders, presumably because of combined

271 disruption of steroid enzyme activity and redox homeostasis (two-hit model). In fact, previous 272 mechanistic studies addressing the impact of human FDXR variants on redox potential in 273 patients' fibroblasts have shown significantly increased ROS production and decreased 274 mitochondrial membrane potential relative to normal fibroblasts, likely due to the excessive 275 buildup of mitochondrial iron in FDXR patient cells (9). Moreover, genetic variants of NNT and TXNRD2, which are involved in maintaining the mitochondrial ROS balance, have been shown 276 277 to be disease causing in several patients with familial glucocorticoid deficiency informing the 278 importance of the mitochondrial ROS system for steroidogenesis (37, 38). In conclusion, adrenal insufficiency might be a potentially fatal, hidden threat to patients with 279 FRM for which they should be screened and treated as indicated. FDXR variants seem to inhibit 280 11-hydroxylase activity predominantly. Therefore, adrenal disease of FRM can also manifest 281 282 with inadequate cortisol production, increased blood pressure, and in 46,XX subjects with 283 ambiguous genitalia at birth or hirsutism/androgen excess later in life.

284

#### 285 METHODS

286 Sex as a biological variable

The impact of FDXR variants in human has been explored in 46,XX individuals (index patients) and in reprogrammed dermal fibroblasts obtained from 46,XY patients. While no investigation of sex as a biological variable can be conducted because of the different methodological approaches (clinical observation vs. steroidogenic profiling in cell) which prevent direct statistical analysis, we confirmed the impact of FDXR mutations on both sexes. Mouse experiments were conducted exclusively in males to reduce the variability linked to the estrous cycle and cannot predict if female recapitulate the phenotype.

294

295 Genetic workup of the index patients

296 For Whole-Exome Sequencing (WES), the amplified DNA fragments were hybridized to the Agilent SureSelect Human All Exon V4 (51 Mb), the captured library was sequenced on a HiSeq 297 298 2000 platform, and the reads were aligned against the human reference genome (GRCh37 at 299 UCSC) to obtain candidate variants. Nuclear variants and indels were prioritized according to 300 the following criteria: (i) variants that were rare in healthy individuals (allele frequency below 301 0.01 for recessive or below 10–5 for dominant model of pathogenesis) or new (not described 302 within public databases); (ii) variants predicted to modify protein function (nonsense, splice site, 303 coding indel, or missense variants); (iii) variants consistent with a recessive model of pathogenesis: homozygous variants or two heterozygous variants present in the same gene; (iv) 304 variants consistent with a dominant model of pathogenesis: heterozygous variants. Additional 305 indications were obtained by using predictive software. Sanger sequencing of the candidate 306 307 gene variant was performed for the patients and the parents. All sequences in this manuscript 308 are annotated using the NM 024417.5 transcript variant.

309

310 In silico analysis

311 Initial analysis using Consurf included multiple sequence alignment of human FDXR with 312 homologs from other species to determine sequence homology and conservation at amino acid substitution sites (39). PolyPhen-2 (Polymorphism Phenotyping v2) was then used to 313 314 gualitatively predict the potential impact of the amino acid substitutions on the structure and function of the FDXR protein (40). The 3D models of human wild-type (WT) (Uniprot: P22570, 315 NCBI: NP 077728) and variant FDXRs were constructed using previously published model-316 317 building protocols based on the crystal structure of bovine FDXR to study the potential impact of mutations on structure (36). Five different x-ray crystal structures of FDXR (PDB: 1E1N, 1CJC, 318 319 1E1K, 1E1M and 1E6E) were used to generate models of human FDXR which were then 320 combined to generate a hybrid model retaining the best parts of individual structures. The

321 modeled structure was then used to understand the structural basis of changes caused by the 322 specific F51L, P74L, R155W, R193H, R386W, and G437R mutations.

The selection of templates was based on BLAST alignment scores, the WHAT\_CHECK quality score (41) in the PDBFinder2 database (42) and the target coverage. For alignment correction and loop modeling, a secondary structure prediction for the target sequence was obtained by running PSI-BLAST to create a target sequence profile and feeding it to the PSI-Pred secondary structure prediction algorithm (43). The stability of mutant proteins was analyzed using DUET (44), mCSM (45), and DynaMut2 (46), and by structural analysis of WT and mutant proteins running as a Python script under Yasara (47).

330

# 331 Studies in reprogrammed cells

332 Human fibroblasts were available for additional studies from previous work and originate from 333 patients II-2 and 2 described by Peng et al., 2017 (9), and patient 14 from Campbell et al. 2023 (19). They carry, respectively, the homozygous FDXR variant c.1156C>T, the c.151T>C and 334 c.1309G>A variants in heterozygosity, and the c.736C>T and c.339G>A variants in 335 336 heterozygosity. Fibroblasts were cultured in Dulbecco's Modified Eagle's Medium supplemented 337 with 10% fetal calf serum (Invitrogen). Deprogramming to induced pluripotent stem cells (iPSC) followed a transgene-free modified Yamanaka protocol (48). Healthy sex-matched control iPSC 338 339 were available from previous projects (49). Reprogramming to adrenal cortex-like cells was performed for both the healthy control line and the three iPSC lines carrying FDXR variant 340 341 according to the Papadopoulos protocol (50). Briefly, a lentivirus was used to induce the expression of NR5A1, parallel to the exposure to dibutyryl cyclic adenosine monophosphate 342 (dbcAMP), desert hedgehog (DHH), and human chorionic gonadotropin (hCG). Two weeks after 343 344 NR5A1 transduction, steroid metabolites in the cell supernatant were measured by liquid 345 chromatography coupled with mass spectrometry (LC-MS) (see Steroid profiling section). Six technical replicates were carried over for each mutant cell line, while two replicates were used 346

for the control line. In addition, three biological replicates were performed in all cases. The
reprogrammed lines carrying a hypofunctional FDXR displayed a slower growth curve compared
to the control line (Figure S1A), therefore raw data expressed in nmol/L (Figure S1B and C)
were normalized by the cell content of glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*)
transcripts (Figure S1D), used as a proxy for cell number, resulting in the normalized values in
Figure 2B that are discussed here.

353

354 Studies in Fdxr<sup>R389W</sup> mice

355 C57BL/6N mice carrying a single point mutation in the *Fdxr* gene (c.1165 C>T), henceforth referred to as '*Fdxr*<sup>R389W'</sup> mice, were generated using CRISPR/Cas9 gene-editing. The 356 genotypes of the knock-in mice were confirmed using PCR and Sanger sequencing, and 357 358 homozygous Fdxr<sup>R389W/R389W</sup> mutant and Fdxr<sup>+/+</sup> control mice were generated by crossing heterozygous *Fdxr*<sup>R389W/+</sup> breeders. For ACTH stimulation testing, age-matched male 359 Fdxr<sup>R389W/R389W</sup> mutant and Fdxr<sup>+/+</sup> control mice between 4-6 weeks of age were selected. ACTH 360 361 stimulation was achieved using intraperitoneal injection of 200 µg human ACTH (Sigma Catalog 362 #A0298) into each mouse on the day of blood and tissue collection. Injections were always 363 performed at the same time in the afternoon (around 3pm local time) to avoid variation due to circadian rhythms. Mice were sacrificed at 1 hour after ACTH injection via CO<sub>2</sub>-mediated 364 euthanasia, and blood was immediately collected via heart puncture. Adrenal gland tissues 365 were also collected from each mouse for subsequent histological analysis. To obtain serum 366 367 samples, the blood samples collected from each mouse were allowed to incubate for 30 minutes at room temperature, and then spun for 10 minutes at 2000g. The serum fraction was then 368 collected from the supernatant and frozen on dry ice before being placed at -80 C for long-term 369 370 storage.

371

372 Immunofluorescence and microscopy

Adrenals were dissected from *Fdxr*<sup>R389W</sup> male mice and strain-, age-, and sex-matched controls, 373 cleared of the surrounding fat tissue and fixed overnight in 4% PFA. 5-um paraffin sections were 374 375 processed for protein immunodetection as previously described (51). Briefly, antigen retrieval 376 was carried out in 10mM Sodium Citrate pH 6.0, followed by overnight incubation with a mouse 377 monoclonal anti-Disabled-2/p96 (Dab2; BD Transduction Laboratories, cat no. 610464), and a rabbit polyclonal anti-Akr1b7 (kindly donated by Dr Pierre Val and Dr Antoine Martinez (52)). 378 379 Indirect staining was performed using the goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody conjugated with Alexa Fluor<sup>™</sup> 488, and a goat anti-mouse IgG (H+L) cross-380 adsorbed secondary antibody conjugated with Alexa Fluor™ 647 (both from Thermo Fisher 381 Scientific, cat. No. A11008 and A21235, respectively). 4',6-diamidino-2-phenylindole (DAPI) was 382 used for nuclear counterstaining. Images were captured using a Nikon Eclipse Ti-E upright 383 384 microscope. Hematoxylin and eosin staining was carried out on neighboring sections with 385 respect to the adrenal-matched immunofluorescence experiment. All hematoxylin and eosin staining experiment in this manuscript were conducted according to standard protocols. 386

387

#### 388 Steroid Profiling

389 Steroid metabolites in the serum of *Fdxr*<sup>R389W</sup> and control mice, as well as in media from reprogrammed patients' cells, were measured by an established in house LC-MS method (53). 390 391 Briefly, samples were collected and stored at -20° C until LC-MS analysis. The samples were purified using a solid-phase extraction on an OasisPrime HLB 96-well plate using a positive 392 pressure 96-well processor (both Waters, UK). For LC-MS analysis, a Vanquish UHPLC 393 (equipped with an ACQUITY UPLC HSS T3 Column, 100Å, 1.8 µm, 1 mm X 100 mm column; 394 Waters, Switzerland) was coupled to a Q Exactive Plus Orbitrap (both Thermo Fisher Scientific, 395 396 Reinach, Switzerland). Separation was achieved using gradient elution over 11 minutes using 397 water and methanol both supplemented with 0.1 % formic acid (all Sigma-Aldrich, Buchs, Switzerland) as mobile phases. Data analysis was performed using TraceFinder 4.1 (Thermo 398

Fisher Scientific, Reinach, Switzerland). The method was validated according to international
standards. Steroid hormone concentrations were calculated in nmol/l. As for data from cell
media, values below quantification or detection thresholds were not used for statistics, unless all
technical/biological replicates for one single condition had values below quantification threshold,
in which case this was indicated in the plot as 'below quantification level' by using the acronym
'BQL'.

405

406 Gene expression analysis

RNA was purified from adrenal-reprogrammed cell monolayers using TRI Reagent (Sigma, 407 T9424) and Direct-zol RNA kits (Zymo Research, R2051), following the manufacturer's 408 409 instructions. A complete protocol is provided in the Supplementary Information. RNA was 410 reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit 411 (Thermo Fisher Scientific, 4368814). Gene expression analysis was carried out by RT-qPCR using the QuantStudio 1 thermocycler (Life Technologies) and the PowerUp™ SYBR™ Green 412 Master Mix (Thermo Fisher Scientific, A25780), according to manufacturer's instructions. 413 414 Technical duplicates were used to control for technical variability. The primers used for RT-415 qPCR were: GAPDH: Fw, GCTCTCTGCTCCTGTTC Rv, CGACCAAATCCGTTGACTCC. 416

417 Statistics

Two-tailed Student's t-tests were used for comparisons between any two groups, while unpaired multiple t-test was carried out when correcting for multiplicity of hypothesis testing unless otherwise specified in the figure legends. Statistical analysis was conducted using the Prism 10 software (GraphPad). The statistical details of the experiments can be found in the figure legends, whereby 'n' values correspond to the number of independent samples. Dot plots are presented as Mean ± Standard Error of the Mean (SEM); for box and whiskers plots, boxes

extend from the 25th to 75th percentiles, the lines in the middle of the box are plotted at themedian, and whiskers extend to the smallest and largest values.

426

427 Study approval

428 Written informed consent was obtained from all patients and/or their parents participating in the

429 study. Ethical approval for the studies of the index patients was from the Instituto de

430 Investigación Hospital 12 de Octubre (i+12) in Madrid, Spain. Ethical approval for the studies

431 with patients' fibroblasts was consented by the Institutional Review Boards of Cincinnati

432 Children's Hospital Medical Center (CCHMC) and State University of New York at Buffalo.

433 Ethical approval for mice studies came from the Cincinnati Children's Hospital Medical Center

and University at Buffalo Institutional Animal Care and Use Committee.

435

436 Data availability

437 Data are available upon reasonable request from the corresponding authors subject to

438 institutional review and approval. Values for all data points in graphs are reported in

the Supporting Data Values file.

# 440 Acknowledgments

We thank our patient participants for their contributions to this study. We thank Dr Efstathios
Katharopoulos for the technical contribution to this work. We thank Dr Pierre Val and Dr Antoine
Martinez for sharing the antibodies used for immunofluorescence. This work was supported by
SNF 320030-146127 (C.E.F.) and the McKeefrey Pediatric Genetics Foundation (T.H.). Panels
A in Figures 1, 2, and 4 were created using BioRender.com.

446

# 447 Authors contributions/email/ORCID iD

- 448 EP: Performed experiments on mice biomaterials. Analyzed data. Created Figures.
- 449 Contributed to manuscript writing; <u>emanuele.pignatti@unibe.ch</u>; ORCID iD 0000-0002-5372-

- 451 JS: Generated and maintained *Fdxr* mouse model. Performed ACTH stimulation
- 452 experiments on mice, and harvested mouse tissue and serum samples. Contributed to
- 453 manuscript writing and reviewing; jslone@buffalo.edu
- 454 EP and JS are co-first authors on this work for equal contributions with EP put first for helping
- the last and corresponding author in overall coordination of the study.
- 456 MAGC: Provided index patient information. Performed clinical workup. Contributed to
- 457 manuscript writing; mariadelosangeles.gomez@salud.madrid.org; ORCID iD 0000-0002-2040-
- 458 0525
- 459 TMC: Patient recruitment. Analysis and interpretation of patient genetic and metabolic testing.
- 460 Contributed to manuscript writing and reviewing; tc74@buffalo.edu
- 461 JV: Performed ACTH stimulation experiments on mice, and harvested mouse tissue and
- 462 serum samples. Contributed to manuscript review. jimmyvu@buffalo.edu
- 463 KSS: Performed experiments on human biomaterials, cell reprogramming. Analyzed data.
- 464 Contributed to manuscript writing; <u>kay.sauter@unibe.ch</u>

- 465 AVP: Bioinformatic structure and docking analyses and predictions. Created Figures.
- 466 Contributed to manuscript writing and reviewing; <u>amit@pandeylab.org</u>
- 467 FMA: Conducted the genetic analysis of index patients; <u>fmartinez@h12o.es</u>; ORCID iD 0000-
- 468 0001-6250-7745.
- 469 MAR: Provided the histological analysis of index patients; marina.alonso@salud.madrid.org;
- 470 ORCID iD 0000-0003-1293-1075.
- 471 DEN: Provided patient biomaterial and labs. <u>dneilson@phoenixchildrens.com</u>; ORCID iD 0000472 0003-4387-9927
- 473 NL: Provided patient biomaterial and labs. <u>Nicola.Longo@hsc.utah.edu</u>
- 474 TdT: Steroid analysis of human and mouse biomaterials. Scientific discussion and manuscript
- 475 writing and reviewing. <u>Therina.dutoit@unibe.ch</u>; ORCID iD 0000-0002-3533-0590.
- 476 CV: Steroid analysis of human and mouse biomaterials. Scientific discussion and manuscript
- 477 writing and reviewing. <u>Clarissa.voegel@unibe.ch</u>
- 478 TH: Study idea and PI. Recruiting patients. Provided patients fibroblast samples for
- 479 experimental analysis. Manuscript writing and review. Co-corresponding author.
- 480 thuang29@buffalo.edu; ORCID iD 0000-0001-6601-6687.
- 481 CEF: Study idea and PI. Overall design, organization, data analysis and interpretation.
- 482 Preparation of figures and tables. Manuscript writing. Corresponding author.
- 483 <u>christa.flueck@unibe.ch;</u> ORCID iD 000-0002-4568-5504
- 484

# 485 **References**

- 4861.Miller WL, Fluck CE, Breault DT, and Feldman BJ. In: Sperling MA ed. Sperling Pediatric487Endocrinology. Philadelphia, PA: Elsevier; 2020.
- 488 2. Pignatti E, and Fluck CE. Adrenal cortex development and related disorders leading to adrenal
  489 insufficiency. *Mol Cell Endocrinol.* 2021;527:111206.
- 4903.Miller WL. Steroidogenic electron-transfer factors and their diseases. Ann Pediatr Endocrinol491Metab. 2021;26(3):138-48.
- Griffin A, Parajes S, Weger M, Zaucker A, Taylor AE, O'Neil DM, et al. Ferredoxin 1b (Fdx1b) Is the
   Essential Mitochondrial Redox Partner for Cortisol Biosynthesis in Zebrafish. *Endocrinology.* 2016;157(3):1122-34.
- 495 5. Oakes JA, Li N, Wistow BRC, Griffin A, Barnard L, Storbeck KH, et al. Ferredoxin 1b Deficiency Leads
  496 to Testis Disorganization, Impaired Spermatogenesis, and Feminization in Zebrafish.
  497 Endocrinology. 2019;160(10):2401-16.
- Freeman MR, Dobritsa A, Gaines P, Segraves WA, and Carlson JR. The dare gene: steroid hormone
  production, olfactory behavior, and neural degeneration in Drosophila. *Development*.
  1999;126(20):4591-602.
- Keizers PH, Mersinli B, Reinle W, Donauer J, Hiruma Y, Hannemann F, et al. A solution model of the complex formed by adrenodoxin and adrenodoxin reductase determined by paramagnetic NMR spectroscopy. *Biochemistry*. 2010;49(32):6846-55.
- Paul A, Drecourt A, Petit F, Deguine DD, Vasnier C, Oufadem M, et al. FDXR Mutations Cause
   Sensorial Neuropathies and Expand the Spectrum of Mitochondrial Fe-S-Synthesis Diseases. *Am J Hum Genet.* 2017;101(4):630-7.
- Peng Y, Shinde DN, Valencia CA, Mo JS, Rosenfeld J, Truitt Cho M, et al. Biallelic mutations in the ferredoxin reductase gene cause novel mitochondriopathy with optic atrophy. *Hum Mol Genet*. 2017;26(24):4937-50.
- Jurkute N, Shanmugarajah PD, Hadjivassiliou M, Higgs J, Vojcic M, Horrocks I, et al. Expanding the
   FDXR-Associated Disease Phenotype: Retinal Dystrophy Is a Recurrent Ocular Feature. *Invest Ophthalmol Vis Sci.* 2021;62(6):2.
- 513 11. Masnada S, Previtali R, Erba P, Beretta E, Camporesi A, Chiapparini L, et al. FDXR-associated
  514 disease: a challenging differential diagnosis with inflammatory peripheral neuropathy. *Neurol Sci.*515 2023;44(9):3037-43.
- Rocatcher A, Desquiret-Dumas V, Charif M, Ferre M, Gohier P, Mirebeau-Prunier D, et al. The top
   most frequently involved genes in hereditary optic neuropathies in 2186 probands. *Brain.* 2023;146(2):455-60.
- 51913.Slone J, Peng Y, Chamberlin A, Harris B, Kaylor J, McDonald MT, et al. Biallelic mutations in FDXR520cause neurodegeneration associated with inflammation. J Hum Genet. 2018;63(12):1211-22.
- 52114.Slone JD, Yang L, Peng Y, Queme LF, Harris B, Rizzo SJS, et al. Integrated analysis of the molecular522pathogenesis of FDXR-associated disease. Cell Death Dis. 2020;11(6):423.
- 52315.Song SJ, Hong Y, Xu K, and Zhang C. Novel biallelic compound heterozygous mutations in FDXR524cause optic atrophy in a young female patient: a case report. Int J Ophthalmol. 2021;14(11):1796-5258.
- 52616.Stenton SL, Piekutowska-Abramczuk D, Kulterer L, Kopajtich R, Claeys KG, Ciara E, et al. Expanding527the clinical and genetic spectrum of FDXR deficiency by functional validation of variants of528uncertain significance. Hum Mutat. 2021;42(3):310-9.
- Yang C, Zhang Y, Li J, Song Z, Yi Z, Li F, et al. Report of a case with ferredoxin reductase (FDXR)
  gene variants in a Chinese boy exhibiting hearing loss, visual impairment, and motor retardation. *Int J Dev Neurosci.* 2021;81(4):364-9.

- Yi S, Zheng Y, Yi Z, Wang Y, Jiang Y, Ouyang J, et al. FDXR-Associated Oculopathy: Congenital Amaurosis and Early-Onset Severe Retinal Dystrophy as Common Presenting Features in a Chinese Population. *Genes (Basel).* 2023;14(4).
- 19. Campbell T, Slone J, Metzger H, Liu W, Sacharow S, Yang A, et al. Clinical study of FDXR-related
   mitochondriopathy: genotype-phenotype correlation and proposal of ancestry-based carrier
   screening in the Mexican population. *Genet Med Open.* 2024.
- 53820.Muller JJ, Lapko A, Bourenkov G, Ruckpaul K, and Heinemann U. Adrenodoxin reductase-539adrenodoxin complex structure suggests electron transfer path in steroid biosynthesis. J Biol540Chem. 2001;276(4):2786-9.
- 54121.Pikuleva IA, Tesh K, Waterman MR, and Kim Y. The tertiary structure of full-length bovine542adrenodoxin suggests functional dimers. Arch Biochem Biophys. 2000;373(1):44-55.
- 54322.Drelon C, Berthon A, Sahut-Barnola I, Mathieu M, Dumontet T, Rodriguez S, et al. PKA inhibits544WNT signalling in adrenal cortex zonation and prevents malignant tumour development. Nat545Commun. 2016;7:12751.
- 546 23. Khattab A, Haider S, Kumar A, Dhawan S, Alam D, Romero R, et al. Clinical, genetic, and structural
  547 basis of congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. *Proc Natl Acad Sci*548 U S A. 2017;114(10):E1933-E40.
- 54924.Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. Mutant P450 oxidoreductase550causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet.5512004;36(3):228-30.
- 552 25. Pandey AV, and Fluck CE. NADPH P450 oxidoreductase: structure, function, and pathology of diseases. *Pharmacol Ther.* 2013;138(2):229-54.
- Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, et al. Diagnosis and management
   of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. *Genet Med.* 2015;17(9):689-701.
- Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, et al. Patient care standards
   for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine
   Society. *Genet Med.* 2017;19(12).
- 560 28. Mills EL, Kelly B, and O'Neill LAJ. Mitochondria are the powerhouses of immunity. *Nat Immunol.*561 2017;18(5):488-98.
- S62 29. Rapoport R, Sklan D, and Hanukoglu I. Electron leakage from the adrenal cortex mitochondrial
  S63 P450scc and P450c11 systems: NADPH and steroid dependence. Arch Biochem Biophys.
  S64 1995;317(2):412-6.
- 56530.Yablokov EO, Sushko TA, Ershov PV, Florinskaya AV, Gnedenko OV, Shkel TV, et al. A large-scale566comparative analysis of affinity, thermodynamics and functional characteristics of interactions of567twelve cytochrome P450 isoforms and their redox partners. *Biochimie.* 2019;162:156-66.
- 56831.Prasad R, Kowalczyk JC, Meimaridou E, Storr HL, and Metherell LA. Oxidative stress and569adrenocortical insufficiency. J Endocrinol. 2014;221(3):R63-73.
- 57032.Bose HS, Sugawara T, Strauss JF, 3rd, and Miller WL. The pathophysiology and genetics of571congenital lipoid adrenal hyperplasia. N Engl J Med. 1996;335(25):1870-8.
- 57233.Corkery-Hayward M, and Metherell LA. Adrenal Dysfunction in Mitochondrial Diseases. Int J Mol573Sci. 2023;24(2).
- 57434.Siri B, D'Alessandro A, Maiorana A, Porzio O, Rava L, Dionisi-Vici C, et al. Adrenocortical function575in patients with Single Large Scale Mitochondrial DNA Deletions: a retrospective single centre576cohort study. Eur J Endocrinol. 2023;189(5):485-94.
- 57735.Zhu J, Eichler F, Biffi A, Duncan CN, Williams DA, and Majzoub JA. The Changing Face of578Adrenoleukodystrophy. Endocr Rev. 2020;41(4):577-93.

- 36. Ziegler GA, and Schulz GE. Crystal structures of adrenodoxin reductase in complex with NADP+
  and NADPH suggesting a mechanism for the electron transfer of an enzyme family. *Biochemistry.*2000;39(36):10986-95.
- Meimaridou E, Kowalczyk J, Guasti L, Hughes CR, Wagner F, Frommolt P, et al. Mutations in NNT
   encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. *Nat Genet*. 2012;44(7):740-2.
- S85 38. Prasad R, Chan LF, Hughes CR, Kaski JP, Kowalczyk JC, Savage MO, et al. Thioredoxin Reductase 2
  (TXNRD2) mutation associated with familial glucocorticoid deficiency (FGD). *J Clin Endocrinol Metab.* 2014;99(8):E1556-63.
- Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T, et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. *Nucleic Acids Res.* 2016;44(W1):W344-50.
- 59140.Adzhubei I, Jordan DM, and Sunyaev SR. Predicting functional effect of human missense mutations592using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7 20.
- 593 41. Vriend G. WHAT IF: a molecular modeling and drug design program. *J Mol Graph.* 1990;8(1):52-6,
  594 29.
- 59542.Touw WG, Baakman C, Black J, te Beek TA, Krieger E, Joosten RP, et al. A series of PDB-related596databanks for everyday needs. Nucleic Acids Res. 2015;43(Database issue):D364-8.
- 597 43. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J
   598 Mol Biol. 1999;292(2):195-202.
- 599 44. Pires DE, Ascher DB, and Blundell TL. DUET: a server for predicting effects of mutations on protein
  600 stability using an integrated computational approach. *Nucleic Acids Res.* 2014;42(Web Server
  601 issue):W314-9.
- 60245.Pires DE, Ascher DB, and Blundell TL. mCSM: predicting the effects of mutations in proteins using603graph-based signatures. *Bioinformatics.* 2014;30(3):335-42.
- 60446.Rodrigues CH, Pires DE, and Ascher DB. DynaMut: predicting the impact of mutations on protein605conformation, flexibility and stability. Nucleic Acids Res. 2018;46(W1):W350-W5.
- 60647.Krieger E, and Vriend G. New ways to boost molecular dynamics simulations. J Comput Chem.6072015;36(13):996-1007.
- 60848.Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to609generate integration-free human iPS cells. Nat Methods. 2011;8(5):409-12.
- 49. Laemmle A, Poms M, Hsu B, Borsuk M, Rufenacht V, Robinson J, et al. Aquaporin 9 induction in
  human iPSC-derived hepatocytes facilitates modeling of ornithine transcarbamylase deficiency. *Hepatology*. 2022;76(3):646-59.
- 50. Li L, Li Y, Sottas C, Culty M, Fan J, Hu Y, et al. Directing differentiation of human induced pluripotent
  stem cells toward androgen-producing Leydig cells rather than adrenal cells. *Proc Natl Acad Sci U S A.* 2019;116(46):23274-83.
- 61651.Pignatti E, Altinkilic EM, Brautigam K, Grossl M, Perren A, Zavolan M, et al. Cholesterol Deprivation617Drives DHEA Biosynthesis in Human Adrenals. Endocrinology. 2022;163(7).
- Aigueperse C, Martinez A, Lefrancois-Martinez AM, Veyssiere G, and Jean CI. Cyclic AMP regulates
  expression of the gene coding for a mouse vas deferens protein related to the aldo-keto reductase
  superfamily in human and murine adrenocortical cells. *J Endocrinol.* 1999;160(1):147-54.
- 53. Andrieu T, du Toit T, Vogt B, Mueller MD, and Groessl M. Parallel targeted and non-targeted quantitative analysis of steroids in human serum and peritoneal fluid by liquid chromatography
  high-resolution mass spectrometry. *Anal Bioanal Chem.* 2022;414(25):7461-72.
- 624

- Table 1. Laboratory findings in two 46,XX index patients with FDXR mutations and
- 626 ambiguous genitalia revealing subclinical, compensated adrenal insufficiency and
- 627 androgen excess.

	Reference range	Sibling A	Sibling B
Sex		46,XX	46,XX
Ambiguous genitalia	at birth	Yes	Yes
Age of demise		9 months	5.5 months
FDXR genotype		c.1309G>C (p.G437R)	c.1309G>C (p.G437R)
		c.1309G>C (p.G437R)	c.1309G>C (p.G437R)
Age at analysis		4 months	4 months
ACTH (pmol/L)	2.2-13.3	31.9/90.9	59.9
Cortisol (nmol/L)	≥140/500*	270	187
17OHProg (nmol/L)	0.57-4.81	5.96	11.8
11-Deoxy-Cortisol	≤7.56	46.6	n.d.
DHEAS (µmol/L)	0.14-1.68	2.75	5.5
A4 (nmol/L)	0.03-6	3.49	4.43
Т	0.1-0.38	0.59	1.35

628

Footnotes:

 $\geq$ 140/500\* - cut-off 140 applies to 8-9 am cortisol value in unstressed patients, cut-off 500 applies to stressed condition due to diseases (e.g., infections) at any time of the day. n.d. - not detected



631 Figure 1. Role of FDXR and genetic characteristics of the FDXR variants identified in the

632 index patients and of the reported patients manifesting with FDXR-Related

# 633 Mitochondriopathy (FRM).

634 (A) Schematic representation of the role of the flavoprotein ferredoxin—NADP(+) reductase

- (FDXR) as electron acceptor from nicotinamide adenine dinucleotide phosphate (NADPH), and
- electron donor for ferredoxin proteins (FDX), from where electrons are finally donated to effector
- 637 Cytochrome P450 (CYP) enzymes associated to the inner mitochondrial membrane. (B)
- 638 Pedigree of a family in which the two daughters are affected by neuropathy and adrenal
- 639 insufficiency caused by the homozygous c.1309G>C (p.G437R) variant in FDXR. (C) displays
- 640 the result of Sanger sequencing around the c.139 region for the members of the family in (B).
- (D) reviews the *FDXR* variants that have been described in FRM patients as of June 2023,
- including the novel p.G437R described in the index patients in this manuscript, aligned to the
- relevant protein domain. Domain annotation is based on a crystallography analysis of the Bos

644 *taurus* FDXR ortholog (36).



# **Figure 2. Cells from FDXR patient display low CYP11B1 and CYP11B2 enzymatic activity.**

647 (A) Classical steroids and steroidogenic pathways, all initiated from cholesterol (top left), occurring in the human adrenal cortex. In red, the official names of the three FDXR-dependent 648 649 mitochondrial steroidogenic enzymes, namely CYP11A1 (also known as 'Cholesterol side-chain 650 cleavage enzyme'), CYP11B2 ('Aldosterone Synthase'), and CYP11B1 ('Steroid 11βhydroxylase'). (B) Steroid amounts in culture media conditioned by reprogrammed fibroblasts 651 652 from FDXR patients compared to control values (representing steroid amounts in culture media conditioned by reprogrammed fibroblasts from a single non affected individual - i.e., 'Control'). 653 Steroids are split among three graphs according to their belonging to a specific steroid class. 654 Arrows containing the names of enzymes indicate the enzymatic reaction carried out by the 655 enzyme. Asterisks reflect discoveries found using a multiple unpaired t test assuming individual 656 657 variance for each steroid. (C) The endpoint or most representative steroids for each pathway on 658 the left, on a linear scale. Statistical analysis was conducted using a one-way ANOVA analysis followed by Dunnett's multiple comparisons test. All values in (B) and (C) are normalized by 659 GAPDH transcripts contained within the cell monolayer, used as a proxy for cell number, as 660 661 reported in Figure S1D. BQL, Below Quantification Level, indicates the samples in which steroid levels were not measurable above the lowest quantification limit using LC-MS. DHEA, 662 Dehydroepiandrosterone. 11-DOC, 11-deoxycorticosterone. \*\*\*\*, adjusted p value < 0.0001. 663





665 Figure 3. Sequence and structure analysis of mutations in FDXR. (A) 3D model of human 666 FDXR displayed as a ribbon diagram. The positions of the phenylalanine 51, proline 74, arginine 667 155, arginine 193, arginine 386, and glycine 437 residues are indicated. The structural model of human FDXR is based on a known 3D structure of the bovine protein as described in the 668 669 methods section. The diagram is colored using a rainbow palette with blue at N-terminus and red at C-terminus. Cofactors (NADP, FAD) are shown as stick models while amino acids 670 671 phenylalanine 51, proline 74, arginine 155, arginine 193, arginine 386, and glycine 437 are shown as spheres. (B) shows the evolutionary sequence conservation of FDXR. Most of the 672 mutations reported in this study are highly conserved across species and are predicted to have 673 structural roles. Sequences are colored based on amino acid conservation, with dark blue being 674 the least conserved and dark red being the most conserved, while yellow indicates no prediction 675 676 could be made. (C) A complex of FDXR and FDX1 proteins showing the locations of mutated 677 residues, which are not at the FDXR-FDX interface and are predicted not to have a direct impact on FDX-FDXR interaction. (D) Stability and flexibility analysis of mutated FDXR 678 679 structures compared to WT FDXR. An increased flexibility was observed for amino acid 680 changes F51L and R193H (shown in red) indicating decreased stability which was supported by 681 differential free energy calculations. Decreased flexibility due to P74L, R155W, R386W and G537R mutations is shown in blue. 682





684 Figure 4. The Fdxr R389W mouse model shows no impairment of adrenal structure and zonation. (A) Schematic of the novel mouse model (Fdxr R389W) carrying homozygous 685 R389W mutations, allelic to the hotspot R386W variant in FDXR patients. (B) Serum steroid 686 profile of the *Fdxr* R389W mice compared to control animals. Asterisks reflect discoveries 687 688 found using a multiple unpaired t test assuming individual variance for each steroid, with False Discovery Rate, and a two-stage step-up method (Benjamini, Krieger, and Yekutieli). (C) Serum 689 690 levels of corticosterone, the main glucocorticoids in mice, in control and *Fdxr* R389W mice. Significance was tested using an unpaired t test. (D) Micrographs of representative adrenal 691 sections, either stained with hematoxylin and eosin (left) or immunoassayed with Dab2 (zona 692 Glomerulosa, zG), Akr1b7 (zona Fasciculata, zF), and 4',6-diamidino-2-phenylindole (DAPI, for 693 nuclei) - right panels. Scale bar = 200um. Dotted white lines outline the zG region as identified 694 695 using Dab2 staining, and the cortico-medullary (med) region (below) as marked by the lower 696 boundary of the Akr1b7 staining. (E) Ratio values calculated as zF area normalized by zG area, measured on 6 independent entire adrenal coronal sections for either controls or Fdxr R389W 697 samples. An unpaired t test was used to calculate significance. \*\*, p value < 0.01; \*\*\*, p value 698 699 <0.001.